Ischemic Preconditioning Clinical Trial
Official title:
A Randomized, Controlled, Open Label Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans
Antiplatelet therapy remains a cornerstone in the treatment of acute and chronic coronary artery disease. Aspirin was the first such therapy to prove its benefits in acute myocardial infarction. Compared to aspirin monotherapy, the combination of aspirin and clopidogrel, a thienopyridine P2Y12 inhibitor, has been demonstrated to reduce adverse event rates among patients with acute coronary syndromes (with or without ST-segment elevation) and those receiving intracoronary stents. In the Triton-TIMI 38 trial a novel thienopyridine, prasugrel, was compared to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Although prasugrel significantly reduced recurrent myocardial infarction, bleeding rates were increased and no improvement in cardiac or all-cause mortality was demonstrated. However, in 2009, the authors of the PLATO trial demonstrated an unexpected cardiovascular mortality benefit with ticagrelor over clopidogrel, an endpoint not previously met by any other antiplatelet agent against an active comparator. Based on the reproducible adverse events seen in the DISPERSE, DISPERSE-2, and PLATO trials, an adenosine-mediated effect of ticagrelor is proposed. Hypothesis: The aim of this study is to test the hypothesis that ticagrelor produces pharmacologic ischemic preconditioning, an undescribed potential off-label property of ticagrelor that could represent a plausible mechanism for its effects on cardiovascular mortality.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01235286 -
Cutaneous Remote Ischemic Preconditioning in Plastic Surgery
|
N/A | |
Completed |
NCT01118000 -
Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning
|
N/A | |
Completed |
NCT00184912 -
The Effect of Caffeine on Ischemic Preconditioning
|
N/A | |
Recruiting |
NCT03380663 -
Conditioning Based Intervention Strategies
|
N/A | |
Completed |
NCT03023150 -
Ischemic Preconditioning as an Intervention to Improve Stroke Rehabilitation - Froedtert
|
N/A | |
Completed |
NCT02981680 -
Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery
|
N/A | |
Completed |
NCT00821522 -
The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery
|
Phase 1 | |
Active, not recruiting |
NCT01164618 -
The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response
|
Phase 2 | |
Not yet recruiting |
NCT05957523 -
Effects of Remote Ischemic Preconditioning on Components of Peripheral Blood and Gut Microbiome (EMINENT)
|
N/A | |
Completed |
NCT04887610 -
Factors That Influence Blood Vessel Regulation During Exercise in Humans
|
N/A | |
Completed |
NCT05219344 -
Tissue Flossing and Lower Limb Neuromuscular Function
|
N/A | |
Completed |
NCT00453531 -
Model System for Transient Forearm Blood Vessel Dysfunction
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412888 -
Effect of CoQ10 on the Endocrine Function of Skeletal Muscle
|
N/A | |
Recruiting |
NCT03900390 -
The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient
|
N/A | |
Completed |
NCT02411266 -
Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage
|
N/A | |
Completed |
NCT02666235 -
Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR)
|
Phase 2 | |
Completed |
NCT04016857 -
Remote Ischemic Preconditioning During Lower Limb Revascularization
|
N/A | |
Not yet recruiting |
NCT05653505 -
Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis
|
||
Completed |
NCT02965547 -
Remote Ischemic Preconditioning of Dynamic Cerebral Autoregulation in Healthy Adults
|
N/A | |
Completed |
NCT05350683 -
Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR
|
Phase 2 |